Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, March 6, 2013 Infinity Pharmaceuticals Inc (NASDAQ:INFI), Up By 7.24% ($3.16) From $43.650 After BUYINS.NET Report Predicted Strength After E
March 6, 2013 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Monday, March 4th 2013 stating that Infinity Pharmaceuticals Inc (NASDAQ:INFI) was expected to be Up After its earnings release. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=infi&id=351608
At the time this story was written, Infinity Pharmaceuticals Inc (NASDAQ:INFI) is Up By 7.24% ($3.16) From $43.650 since the BUYINS.NET report was released.
The movement of stock prices in the days and weeks leading to and following earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php
Infinity Pharmaceuticals Inc (NASDAQ:INFI) - Infinity Pharmaceuticals, Inc., a drug discovery and development company, focuses on discovering, developing, and delivering medicines to patients for diseases with significant unmet need. Its lead product candidates include IPI-145 and IPI-443, inhibitors of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K); and Retaspimycin HCl, a heat shock protein 90 inhibitor. The company is pursuing a dual development path for IPI-145 in both hematologic malignancies and inflammation. IPI-145 is in an ongoing Phase I dose-escalation trial in patients with advanced hematologic malignancies and in a Phase II study in patients with mild, allergic asthma. In addition, the company plans to initiate a Phase IIa signal-finding study in patients with rheumatoid arthritis. IPI-443 is undergoing preclinical studies to enable Phase I development. Retaspimycin HCl is in a Phase II trial in combination with docetaxel to treat patients with non-small cell lung cancer (NSCLC) and in an exploratory Phase Ib/II trial in combination with everolimus in NSCLC patients with a KRAS mutation. The company is headquartered in Cambridge, Massachusetts..
About BUYINS.NET
BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:
REGULATORY & COMPLIANCE NEWS
Friction Factor -- market-maker surveillance system tracking market makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements".
RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions.
INVESTMENTS & TRADING
SqueezeTrigger -- 28 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.
Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.
Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.
Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.
Pattern Scan -- automates tracking of every technical pattern and predicts next move in stocks.
GATS -- tracks and quantifies known trading strategies.
DISCLAIMER:
BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. Infinity Pharmaceuticals Inc (NASDAQ:INFI) has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.
Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net
- WOPRAI
- support@woprai.com